Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism

•COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.•Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.•Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.

Saved in:
Bibliographic Details
Published inThrombosis research Vol. 192; pp. 113 - 115
Main Authors Galeano-Valle, F., Oblitas, C.M., Ferreiro-Mazón, M.M., Alonso-Muñoz, J., del Toro-Cervera, J., di Natale, M., Demelo-Rodríguez, P.
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 01.08.2020
Subjects
Antibodies, Antiphospholipid
Antiphospholipid Syndrome
Betacoronavirus
Coronavirus Infections
COVID-19
Humans
Lupus Coagulation Inhibitor
Pandemics
Pneumonia, Viral
SARS-CoV-2
Venous Thromboembolism
Online AccessGet full text

Cover

More Information
Summary:•COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.•Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.•Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0049-3848
1879-2472
1879-2472
DOI:10.1016/j.thromres.2020.05.017